Vanguard Group
NXTC icon

Vanguard Group’s NextCure NXTC Stock Holding History

Vanguard Group’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.3M Buy
91,910
+23,927
+35% +$248K ﹤0.01% 3705
2025
Q3 		$398K Sell
67,983
-4,685
-6% -$24.5K ﹤0.01% 4001
2025
Q2 		$401K Sell
72,668
-9,609
-12% -$51.6K ﹤0.01% 3970
2025
Q1 		$474K Hold
82,277
– – ﹤0.01% 3900
2024
Q4 		$761K Hold
82,277
– – ﹤0.01% 3835
2024
Q3 		$1.35M Hold
82,277
– – ﹤0.01% 3681
2024
Q2 		$1.57M Hold
82,277
– – ﹤0.01% 3640
2024
Q1 		$2.2M Buy
82,277
+6,975
+9% +$120K ﹤0.01% 3561
2023
Q4 		$1.03M Buy
75,302
+16
+0% +$232 ﹤0.01% 3820
2023
Q3 		$1.17M Sell
75,286
-420
-0.6% -$8.01K ﹤0.01% 3779
2023
Q2 		$1.64M Hold
75,706
– – ﹤0.01% 3728
2023
Q1 		$1.34M Hold
75,706
– – ﹤0.01% 3817
2022
Q4 		$1.28M Buy
75,706
+27
+0% +$621 ﹤0.01% 3826
2022
Q3 		$2.5M Sell
75,679
-2,184
-3% -$111K ﹤0.01% 3663
2022
Q2 		$4.39M Buy
77,863
+20,381
+35% +$1.06M ﹤0.01% 3439
2022
Q1 		$3.35M Sell
57,482
-5,149
-8% -$322K ﹤0.01% 3723
2021
Q4 		$4.51M Sell
62,631
-4,603
-7% -$385K ﹤0.01% 3667
2021
Q3 		$5.44M Buy
67,234
+132
+0.2% +$11.6K ﹤0.01% 3602
2021
Q2 		$6.47M Sell
67,102
-3,255
-5% -$333K ﹤0.01% 3451
2021
Q1 		$8.45M Buy
70,357
+9,556
+16% +$1.38M ﹤0.01% 3242
2020
Q4 		$7.95M Buy
60,801
+3,467
+6% +$448K ﹤0.01% 3111
2020
Q3 		$6.05M Buy
57,334
+637
+1% +$78.3K ﹤0.01% 3050
2020
Q2 		$14.6M Buy
56,697
+6,304
+13% +$2.4M ﹤0.01% 2575
2020
Q1 		$22.4M Buy
50,393
+3,043
+6% +$1.63M ﹤0.01% 2232
2019
Q4 		$32M Buy
47,350
+28,093
+146% +$14.1M ﹤0.01% 2312
2019
Q3 		$7.13M Buy
19,257
+8,317
+76% +$2.7M ﹤0.01% 2998
2019
Q2 		$1.97M Buy
+10,940
New +$2.27M ﹤0.01% 3479

Other funds holding NXTC

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's NXTC Position: Q4 2025 in Review

Vanguard Group increased its NextCure (NXTC) stake by 35% in Q4 2025, buying an estimated $248K and bringing the position to 91,910 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3705.

Vanguard Group first reported a position in NXTC in Q2 2019 and has held it in 27 quarters since. The position peaked at $32M in Q4 2019. 24 funds tracked by Wall St. Rank hold NXTC as of Q4 2025.

  • Vanguard Group held 91,910 shares of NextCure worth $1.3M as of Q4 2025.
  • Vanguard Group bought 23,927 NextCure shares in Q4 2025, an estimated $248K.
  • NextCure made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3705 holding.
  • Vanguard Group first reported a position in NextCure in Q2 2019 and has held it in 27 quarters since.
  • Vanguard Group's NextCure position peaked at $32M in Q4 2019.
  • 24 funds tracked by Wall St. Rank held NextCure as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.